Yoshiko Okikawa

Clinical Significance of sIL-2R Levels in B-Cell Lymphomas

Noriaki Yoshida, Miyo Oda, Yoshiaki Kuroda et al. · PLoS ONE · 2013 · 59 citations · Full text

Medicine, Hematology, Immunology +17

Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival

Takayoshi Kiba, Takuo Ito, Toshihisa Nakashima et al. · BMC Cancer · 2014 · 44 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation

Shoso Munemasa, Akira Sakai, Yoshiaki Kuroda et al. · International Journal of Oncology · 2008 · 42 citations · Full text

Medicine, Oncology, Pharmacology +15

Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia

Jun Imagawa, Yuka Harada, Takeshi Shimomura et al. · Blood · 2010 · 23 citations · Full text

Medicine, Hematology, Oncology +16

A case of primary extranodal natural killer/T-cell lymphoma in the orbit and intraocular tissues with cerebrospinal fluid involvement

Arisa Okada, Yosuke Harada, Tomoko Inoue et al. · American Journal of Ophthalmology Case Reports · 2018 · 19 citations · Full text

Medicine, Oncology, Ophthalmology +17